CMMB

Chemomab Therapeutics Ltd. CMMB

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-8.99M

Quarter to Dec 31

Free cash flow

$-11.13M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$615.3K total
CITADEL ADVISORS LLC
$154.4K+48.5%
ADAR1 Capital Management, LLC
$129.6K0.0%
KESTRA PRIVATE WEALTH SERVICES, LLC
$100.0K0.0%
Ikarian Capital, LLC
$83.9K0.0%
RHUMBLINE ADVISERS
$49.5K+66.2%
XTX Topco Ltd
$25.9K-14.2%
Philadelphia Investment Partners, LLC
$24.3K+82.9%
Lido Advisors, LLC
$23.2KNew
BNP PARIBAS FINANCIAL MARKETS
$11.0K-19.2%
GAMMA Investing LLC
$7.7K-37.5%
MORGAN STANLEY
$5.8K-21.9%
SBI Securities Co., Ltd.
$55+21.4%
Caitong International Asset Management Co., Ltd
$130.0%
See all 13 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CMMB

Earnings Per Share

13fpro.ai/company/CMMB

Loading ratio trend…

CMMB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Chemomab Therapeutics Ltd. (CMMB): stock profile, AI score and financials

Chemomab Therapeutics Ltd. (CMMB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CMMB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Chemomab Therapeutics Ltd. reports net income of $-9.0M, free cash flow of $-11.1M. Top institutional holders of CMMB by reported 13-F value include CITADEL ADVISORS, ADAR1 Capital Management, KESTRA PRIVATE WEALTH SERVICES, based on the most recent SEC filings. CMMB trades on the Nasdaq exchange and files with the SEC under CIK 1534248. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CMMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Chemomab Therapeutics Ltd. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1534248 →